Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension Cohort
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Aplastic Anemia
Conditions
Severe Aplastic Anemia
Trial Timeline
Jul 2, 2012 → Nov 30, 2029
NCT ID
NCT01623167About Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension Cohort
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension Cohort is a phase 1/2 stage product being developed by Novartis for Severe Aplastic Anemia. The current trial status is active. This product is registered under clinical trial identifier NCT01623167. Target conditions include Severe Aplastic Anemia.
What happened to similar drugs?
20 of 20 similar drugs in Severe Aplastic Anemia were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01623167 | Phase 1/2 | Active |
Competing Products
20 competing products in Severe Aplastic Anemia